Pro Share Advisors LLC Natera, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$30.32 - $91.33 $66,976 - $201,747	-2,209 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$86.26 - $119.0 $12,507 - $17,255	145 Added 7.03%	2,209 $206,000
Q3 2021 Nov 12, 2021	BUY	$100.17 - $126.36 $206,750 - $260,807	2,064 New	2,064 $230,000
Q2 2021 Aug 13, 2021	SELL	$86.05 - $119.72 $1.74 Million - $2.42 Million	-20,215 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$91.47 - $124.36 $315,845 - $429,415	3,453 Added 20.6%	20,215 $2.05 Million
Q4 2020 Feb 09, 2021	BUY	$66.66 - $111.74 $538,812 - $903,194	8,083 Added 93.13%	16,762 $1.67 Million
Q3 2020 Nov 13, 2020	SELL	$45.89 - $72.67 $36,803 - $58,281	-802 Reduced 8.46%	8,679 $627,000
Q2 2020 Aug 03, 2020	BUY	$26.36 - $49.86 $249,919 - $472,722	9,481 New	9,481 $473,000
Q1 2020 May 15, 2020	SELL	$17.27 - $40.17 $145,931 - $339,436	-8,450 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$32.1 - $40.4 $66,607 - $83,830	2,075 Added 32.55%	8,450 $285,000
Q3 2019 Nov 12, 2019	BUY	$25.38 - $34.89 $161,797 - $222,423	6,375 New	6,375 $209,000

526

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.2B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.